Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Urothelial Cancer of Renal Pelvis: full-pipeline trial registry
2 of 3 indexed Urothelial Cancer of Renal Pelvis trials are currently recruiting.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Urothelial Cancer of Renal Pelvis: 3 US clinical trials tracked, 2 recruiting.
Urothelial Cancer of Renal Pelvis is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Case Comprehensive Cancer Center, running 1 of these trials.
Enrollment posture brief
Registry condition urothelial-cancer-of-renal-pelvis
OPEN 2 | RECR 67% | LATE 1 | EARLY 1 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Urothelial Cancer of Renal Pelvis lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Urothelial Cancer of Renal Pelvis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Urothelial Cancer of Renal Pelvis is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
UroGen Pharma
NCT05874921
Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma
University of Texas Southwestern Medical Center
NCT04865939
Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer
Case Comprehensive Cancer Center
NCT04620603
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Urothelial Cancer of Renal Pelvis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Urothelial Cancer of Renal Pelvis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Urothelial Cancer of Renal Pelvis page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Urothelial Cancer of Renal Pelvis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Case Comprehensive Cancer Center sponsors the most Urothelial Cancer of Renal Pelvis trials on record, review their full trial history before evaluating a specific study. See Case Comprehensive Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Urothelial Cancer of Renal Pelvis condition card totals 3 registered trials; most-linked intervention Standard-of-Care Immunotherapy; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.